ArticleCancer research and treatment2026
Effectiveness of CAR-T Cell Therapies for Relapsed/Refractory Follicular Lymphoma: An External Control Arm Study.
Article in Cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anbalcabtagene Autoleucel: First Approval.Molecular diagnosis & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purpose: Axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) have received regulatory approval for relapsed or refractory follicular lymphoma (FL). However, the data are scarce on their comparative effectiveness against the salvage therapies available in real-world settings. This study aimed to indirectly compare treatment outcomes of axi-cel, tisa-cel, and liso-cel versus usual care in South Korean patients with FL. Materials and Methods: To assess effectiveness in real-world data, aggregate data from the ZUMA-5, ELARA, and TRANSCEND FL studies were compared with individual patient data from the Samsung Medical Center-Lymphoma Cohort Study (SMC-LCS). Patients meeting ZUMA-5, ELARA, and TRANSCEND FL eligibility criteria were selected as the external control arm. All eligible treatment lines per patient were analyzed as independent episodes and weighted using the matching-adjusted indirect comparison method. Timeto-event outcomes were assessed with weighted Kaplan-Meier analysis, and adjusted hazard ratios (HRs) were estimated using Cox proportional hazards models. Results: Axi-cel included 127 patients, tisa-cel included 94, liso-cel included 101, and 121 episodes from 49 patients were analyzed in the external control arm. The weighted HRs for overall survival and progression-free survival for axi-cel versus the external control were 0.37 (95% confidence interval [CI], 0.21 to 0.64) and 0.35 (95% CI, 0.20 to 0.59), respectively. For tisa-cel, the HRs were 0.24 (95% CI, 0.11 to 0.53), and 0.35 (95% CI, 0.20 to 0.60), respectively. For liso-cel, the HRs were 0.38 (95% CI, 0.13 to 1.04) and 0.36 (95% CI, 0.15 to 0.88), respectively. Conclusion: All three chimeric antigen receptor T-cell therapies showed outstanding effectiveness compared to conventional treatments in usual care in South Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.